AMWL — American Well Corporation

Amwell (AMWL) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $56.3 million, an 8% decrease year-over-year, primarily due to the divestiture of Amwell Psychiatric Care (APC) and reduced contributions from Leidos. Normalized revenue would have increased by 1.3%.
• Subscription Revenue: $30.9 million, up 18% year-over-year, now representing 55% of total revenue (compared to 43% last year).
• Visit Volume: Approximately 1.1 million visits, down 21% year-over-year, but aligned with expectations. Amwell Medical Group (AMG) visit revenue decreased by 23% to $21.2 million.
• Average Revenue per Visit: $71, a 14% decline year-over-year, but normalized for APC sale, it showed a 3.5% increase.
• GAAP Gross Margin: Expanded to 52% from 37% year-over-year.
• Operating Expenses: $58.9 million, a 16% decrease from last year, with significant reductions in R&D (6%), sales and marketing (46%), and G&A (14%).
• Adjusted EBITDA: Loss of $12.7 million, improved from a loss of $31 million a year ago.
• Cash Position: Approximately $201 million in cash and marketable securities, with no debt.

2. Strategic Updates and Business Highlights

• Amwell is focused on achieving cash flow breakeven by the end of 2026 through two main initiatives: enhancing their enterprise-grade platform and improving operational efficiency.
• The integration of AI technologies is central to their strategy, aimed at transforming patient intake and clinical program matching.
• The company is divesting non-core assets to concentrate resources on high-margin growth opportunities, with a commitment to maintain support for legacy products during the transition.
• Positive market trends include increased consumer demand for digital health solutions and a growing recognition of the need for integrated care solutions among health systems.

3. Forward Guidance and Outlook

• Full Year Revenue Guidance: Expected between $245 million and $248 million, slightly revised down from the previous range.
• Adjusted EBITDA Guidance: Projected loss between $45 million and $42 million, improved from prior estimates.
• Q4 Revenue Guidance: Anticipated between $51 million and $54 million, with adjusted EBITDA losses between $15 million and $12 million.
• The company aims to reduce R&D expenses by over 10% and sales and marketing costs by more than 25% year-over-year.

4. Bad News, Challenges, or Points of Concern

• Declining Visit Volume: A 21% year-over-year decrease in total visit volume raises concerns about demand and utilization of services.
• Revenue Decline: Overall revenue decline, particularly from key partnerships, could indicate challenges in customer retention and market competitiveness.
• Market Fragmentation: While there is growing demand for integrated solutions, the complexity and fragmentation in the digital health market pose risks for customer acquisition and retention.
• Economic Uncertainty: Potential impacts from macroeconomic factors and health systems evaluating IT budgets may affect future sales pipelines.

5. Notable Q&A Insights

• Competitive Wins: Amwell's recent win with Florida Blue was attributed to their ability to provide a unified platform that reduces vendor fatigue and complexity, indicating a competitive edge in the market.
• Divestiture Strategy: The company is actively pursuing the divestiture of non-core assets to focus on high-ROI opportunities, although these actions are not yet reflected in current guidance.
• AI Monetization: AI integration is expected to enhance customer ROI through improved patient experiences and operational efficiencies, although immediate pricing impacts are not anticipated.
• Customer Retention Focus: Retaining existing clients is prioritized as a key factor for achieving cash flow breakeven, with a strong emphasis on delivering measurable economic value.

Overall, Amwell is navigating a challenging environment with strategic initiatives aimed at long-term growth, while addressing immediate financial pressures and market dynamics.